IMMX

Immix Biopharma, Inc. NASDAQ Listed Dec 16, 2021

Healthcare ·Biotechnology ·US · immixbio.com

$9.54

Mkt Cap $506.0M

52w Low $1.87 78.8% of range 52w High $11.61

50d MA $9.35 200d MA $5.32

P/E (TTM) -10.4x

EV/EBITDA -3.0x

P/B 3.3x

Debt/Equity 0.0x

ROE -222.2%

P/FCF -7.0x

RSI (14) —

ATR (14) —

Beta 0.21

50d MA $9.35

200d MA $5.32

Avg Volume 789.5K

Immix Biopharma, Inc., a clinical-stage biopharmaceutical company, engages in developing various tissue-specific therapeutics in oncology and inflammation in the United States and Australia. The company is developing IMX-110 that is in Phase 1b/2a clinical trials for the treatment of soft tissue sarcoma and solid tumors; IMX-111, a tissue-specific biologic for the treatment of colorectal cancers; and IMX-120, a tissue-specific biologic for the treatment of ulcerative colitis and severe Crohn's disease. It has a clinical collaboration and supply agreement with BeiGene Ltd. for a combination Phase 1b clinical trial in solid tumors of IMX-110 and anti-PD-1 Tislelizumab. The company was incorporated in 2012 and is headquartered in Los Angeles, California.

SIC Code

2834

CIK (SEC)

1873835

Phone

310 651 8041

11400 West Olympic Boulevard · Los Angeles, CA 90064 · US

Date	Time	Est	Rptd	Surp	Base	Gap%	D1%	D2%	D3%	D4%	D5%	Guide ▲★
Mar 25, 2026	AMC	-0.21	-0.27	-28.6%	8.91	-8.8%	-2.1%	-6.5%	+5.3%	+6.2%	-5.4%	—
Nov 7, 2025	AMC	-0.19	-0.24	-26.3%	3.15	+3.5%	+2.9%	-0.3%	+15.2%	-3.0%	+16.6%	—
Aug 8, 2025	AMC	-0.21	-0.22	-4.8%	2.39	+0.0%	-2.9%	-0.9%	+1.3%	-6.0%	+3.7%	—
May 8, 2025	AMC	-0.23	-0.15	+34.8%	2.15	-2.3%	-2.8%	+0.0%	-5.3%	+0.0%	+5.6%	—
Mar 24, 2025	AMC	-0.25	-0.16	+36.0%	1.82	+0.0%	+1.6%	-1.1%	-6.6%	-0.6%	-1.2%	—
Nov 12, 2024	AMC	-0.16	-0.24	-50.0%	1.72	-1.7%	-8.7%	+3.2%	-1.9%	+6.3%	+0.6%	—
Aug 12, 2024	AMC	-0.21	-0.15	+28.6%	1.85	+0.0%	+0.5%	+2.7%	-1.0%	+0.5%	+10.0%	—
May 9, 2024	AMC	-0.23	-0.22	+4.3%	2.18	-5.5%	+0.0%	-0.9%	+1.9%	+6.8%	-4.3%	—
Mar 29, 2024	AMC	-0.23	-0.24	-4.3%	—	—	—	—	—	—	—	—
Nov 9, 2023	AMC	-0.23	-0.23	+0.0%	3.71	+0.0%	+12.9%	+1.4%	+3.5%	+1.4%	-0.2%	—
Aug 11, 2023	AMC	-0.17	-0.24	-41.2%	1.82	-1.1%	+0.5%	+1.6%	-4.8%	-7.9%	+6.1%	—
May 12, 2023	AMC	-0.14	-0.18	-28.6%	2.13	-1.4%	-3.3%	-10.2%	-4.3%	+7.9%	-14.1%	—

Date	Firm	Action	Grade	Target	Base	Open	Gap%	D1%	D2%	D3%	D4%	D5%
Mar 30	HC Wainwright & Co.	Maintains	Buy → Buy	—	$8.15	$8.19	+0.5%	+5.3%	+6.2%	-5.4%	+3.7%	-3.9%
Mar 30	Mizuho	Maintains	Outperform → Outperform	—	$8.15	$8.19	+0.5%	+5.3%	+6.2%	-5.4%	+3.7%	-3.9%
Mar 27	Citizens	Maintains	Market Outperform → Market Outperform	—	$8.72	$8.97	+2.9%	-6.5%	+5.3%	+6.2%	-5.4%	+3.7%
Mar 27	HC Wainwright & Co.	Maintains	Buy → Buy	—	$8.72	$8.97	+2.9%	-6.5%	+5.3%	+6.2%	-5.4%	+3.7%
Dec 9	HC Wainwright & Co.	Maintains	Buy → Buy	—	$6.15	$6.30	+2.4%	+7.3%	+2.0%	+9.7%	-4.2%	-12.2%
Sep 12	HC Wainwright & Co.	Maintains	Buy → Buy	—	$2.22	$2.22	+0.0%	-5.4%	-0.5%	-4.3%	-2.0%	+6.6%
Jun 4	HC Wainwright & Co.	Maintains	Buy → Buy	—	$2.11	$2.07	-1.9%	-2.4%	+6.3%	+8.2%	-1.3%	+3.0%
Feb 10	HC Wainwright & Co.	Maintains	Buy → Buy	—	$2.01	$1.96	-2.5%	-2.0%	+0.0%	+1.0%	+0.0%	-0.5%
Jan 6	HC Wainwright & Co.	Maintains	Buy → Buy	—	$2.35	$2.40	+2.1%	-2.1%	-0.9%	-1.3%	-6.7%	+1.0%
Oct 3	HC Wainwright & Co.	Maintains	Buy → Buy	—	$1.46	$1.48	+1.4%	-8.2%	+21.6%	-11.0%	+5.5%	+0.7%
Aug 19	HC Wainwright & Co.	Maintains	Buy → Buy	—	$1.90	$1.90	+0.0%	+10.0%	+3.8%	+5.1%	-3.1%	-2.7%
Jul 26	HC Wainwright & Co.	Maintains	Buy → Buy	—	$2.15	$2.16	+0.5%	+4.2%	-5.8%	+6.6%	-8.0%	+0.5%
Jul 9	HC Wainwright & Co.	Maintains	Buy → Buy	—	$2.16	$2.23	+3.2%	+1.9%	-7.3%	-1.5%	+5.0%	-3.3%
Aug 14	Roth MKM	Maintains	Buy → Buy	—	$1.82	$1.80	-1.1%	+0.5%	+1.6%	-4.8%	-7.9%	+6.1%
Feb 22	Roth MKM	Maintains	Buy → Buy	—	$2.07	$2.30	+11.1%	+12.1%	-3.4%	-4.0%	-0.5%	-2.8%

Data updated apr 25, 2026 3:18pm · Source: massive.com